News

Merck said that it anticipates FDA action in the second quarter of 2008. The company added that it is also moving forward as planned with filings in countries

The proof of concept clinical trial demonstrated safety and appropriate dosing of the combination regimen and showed promising clinical responses in patients under 60 years of age. Complete

The FDA stated that Fast Track designation was granted for oral azacitidine for myelodysplastic syndromes (MDS) because azacitidine, known in its injectable form as Vidaza, is approved to

The first Phase I study of the compound, PRLX 93936, will be a dose-escalating trial involving up to 36 patients. PRLX 93936 is a structural analog of a

Methylnaltrexone is a peripherally acting mu-opioid receptor antagonist that is designed to treat opioid-induced constipation (OIC) without interfering with pain relief. A new drug application for the subcutaneous

The agreement covers both an initial research collaboration and an option to Teva for a worldwide exclusive development and commercialization license. CGEN-54, a drug candidate for chronic inflammatory

ALS-357 is a novel drug entering Phase I/II clinical development that has demonstrated potent anti-tumor activity against malignant melanoma. Rapid tumor regression has been shown in a mouse

The double-blind, placebo-controlled trial will evaluate safety, tolerability and immune responses in up to 60 healthy volunteers aged 18 to 45 at two US clinical sites. According to

The trial is being conducted at multiple sites in the European Union. Patients under the age of 60 with relapsed or refractory acute myeloid leukemia (AML), or patients